Vertex has announced the results of their Phase 2 Study C208 which explored the use of telaprevir-based regimen in hepatitis C patients. The study which showed more than 80% of patients responded is to be represented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which began yesterday in Boston.
Vertex has announced the results of their Phase 2 Study C208 which explored the use of telaprevir-based regimen in hepatitis C patients.
Source:
Ramona Bates MD 
